HRP20110551T1 - Antagonisti cikličkog peptida cxcr4 - Google Patents
Antagonisti cikličkog peptida cxcr4 Download PDFInfo
- Publication number
- HRP20110551T1 HRP20110551T1 HR20110551T HRP20110551T HRP20110551T1 HR P20110551 T1 HRP20110551 T1 HR P20110551T1 HR 20110551 T HR20110551 T HR 20110551T HR P20110551 T HRP20110551 T HR P20110551T HR P20110551 T1 HRP20110551 T1 HR P20110551T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- glu
- lys
- absent
- asp
- Prior art date
Links
- 108010069514 Cyclic Peptides Proteins 0.000 title 1
- 102000001189 Cyclic Peptides Human genes 0.000 title 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 title 1
- 150000003951 lactams Chemical class 0.000 claims abstract 26
- -1 n-hexanoyl Chemical group 0.000 claims abstract 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 16
- 150000003839 salts Chemical class 0.000 claims abstract 15
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims abstract 15
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims abstract 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 10
- 125000003277 amino group Chemical group 0.000 claims abstract 8
- 244000137850 Marrubium vulgare Species 0.000 claims abstract 7
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims abstract 6
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 claims abstract 6
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims abstract 5
- DTERQYGMUDWYAZ-UHFFFAOYSA-N N-acetyl-N-thioacetyl-Lysine Natural products CC(=O)NCCCCC(N)C(O)=O DTERQYGMUDWYAZ-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims abstract 5
- QCXJEYYXVJIFCE-UHFFFAOYSA-N para-acetamidobenzoic acid Natural products CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims abstract 3
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract 3
- 125000001424 substituent group Chemical group 0.000 claims abstract 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 8
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 8
- XXEWFEBMSGLYBY-ZETCQYMHSA-N N(6),N(6)-dimethyl-L-lysine Chemical compound CN(C)CCCC[C@H](N)C(O)=O XXEWFEBMSGLYBY-ZETCQYMHSA-N 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 abstract 4
- 125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 abstract 3
- 125000004077 D-glutamic acid group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(N([H])[H])=O 0.000 abstract 3
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Laktamski ciklizirani peptid formule I: R1 - ciklo[X1 - Tyr - X3 - DArg - 2Nal - Gly - X7] - X8 - X9 - X10 - R2 (I) (SEQ ID NO:1) naznačen time što: a) navedeni laktam se tvori amidnom vezom između amino skupine u pobočnom lancu u X1 i karboksilne skupine u pobočnom lancu u X7, gdje X1 i X7 čine par, koji se bira iz skupine koju čine (D/L)Agl/Glu, Dab/Glu, te Dap/Glu, a R1 je Ac ili n-heksanoil; ilib) navedeni laktam tvori se amidnom vezom između karboksilne skupine u pobočnom lancu u X1 i amino skupine u pobočnom lancu u X7, gdje X1 i X7 čine par, koji se bira iz skupine koju čine Asp/(D/L)Agl, Asp/Dab, Asp/Dap, Glu/(D/L)Agl, Glu/Dab, Glu/Dap, Glu/DDap, te Glu/Lys, te R1 je Ac ili Bz, ili gdje X1 i X7 čine par, koji se bira iz skupine koju čine sukcinil/(D/L)Agl, sukcinil/Dab, sukcinil/Dap, sukcinil/Lys, te sukcinil/Orn, a R1 je odsutan; ilic) navedeni laktam tvori se amidnom vezom između α-amino skupine u X1 i karboksilne skupine u pobočnom lancu u X7, gdje X1 i X7 čine par, koji se bira iz skupine koju čine Ala/Glu, Ala/DGlu, DAla/Glu, DAla/DGlu, Dap(Ac)/Glu, Gly/Asp, Gly/Glu, Gly/DGlu, Leu/Glu, Leu/DGlu, Lys/DGlu, Lys(Ac)/Glu, 2Nal/Glu, Phe/Glu, Phe/DGlu, DPhe/Glu, te DPhe/DGlu, a R1 je odsutan; ilid) navedeni laktam tvori se amidnom vezom između amino skupine u X1, koja nije ni α- niti amino skupina u pobočnom lancu, i karboksilne skupine u pobočnom lancu u X7, gdje X1 i X7 čine par, koji se bira iz skupine koju čine ?-Ala/Asp, ?-Ala/Glu, 5-aminovaleril/Asp, 5-aminovaleril/Glu, 4-AMB/Glu, 4-AMPA/Asp, te 4-AMPA/Glu, a R1 je odsutan; ilie) navedeni laktam tvori se amidnom vezom između α-amino skupine u X2 i karboksilne skupine u pobočnom lancu u X7, gdje X2 i X7 čine par, koji se bira iz skupine koju čine Tyr/Asp, Tyr/Glu, te Tyr/DGlu, a svaki od R1 i X1 je odsutan; R1 je supstituent na α-amino skupini u X1 kada X1 sadrži α-amino skupinu, a navedena α-amino skupina nije sastavni dio navedene laktamske amidne veze, koji se bira iz skupine koju čine Ac, Bz, te n-heksanoil, ili je odsutan, gdje X1 se bira iz skupine koju čine (D/L)Agl, Asp, Dab, Dap, te Glu; X1 se bira iz skupine koju čine (D/L)Agl, Ala, ?-Ala, DAla, 5-aminovaleril, 4-AMB, 4-AMPA, Asp, Dab, Dap, Dap(Ac), Glu, Gly, Leu, Lys, Lys(Ac), 2Nal, Phe, DPhe, te sukcinil, ili je odsutan; X3 se bira iz skupine koju čine Arg, Lys, Lys(iPr), te Lys(Me2);X7 se bira iz skupine koju čine (D/L)Agl, Asp, Dab, Dap, DDap, Glu, DGlu, Lys, te Orn; X8 se bira iz skupine koju čine ?-Ala, Arg, DArg, Gly, Lys, Lys(iPr), te Orn, ili je odsutan; X9 se bira iz skupine koju čine Gly, 2Nal, D2Nal, te DPhe, ili je odsutan; X10 je 2Nal, ili je odsutan; gdje kada X8 je odsutan, svaki od X9 i X10 je odsutan, a kada X9 je odsutan, X10 je odsutan, iR2 se bira iz skupine koju čine NH2 i NHEt, ilinjegova farmaceutski prihvatljiva sol. Patent sadrži još 12 patentnih zahtjeva.
Claims (13)
1. Laktamski ciklizirani peptid formule I:
R1 - ciklo[X1 - Tyr - X3 - dArg - 2Nal - Gly - X7] - X8 - X9 - X10 - R2 (I) (SEQ ID NO:1)
naznačen time što:
a) navedeni laktam se tvori amidnom vezom između amino skupine u pobočnom lancu u X1 i karboksilne skupine u pobočnom lancu u X7, gdje X1 i X7 čine par, koji se bira iz skupine koju čine (d/l)Agl/Glu, Dab/Glu, te Dap/Glu, a R1 je Ac ili n-heksanoil; ili
b) navedeni laktam tvori se amidnom vezom između karboksilne skupine u pobočnom lancu u X1 i amino skupine u pobočnom lancu u X7, gdje X1 i X7 čine par, koji se bira iz skupine koju čine Asp/(d/l)Agl, Asp/Dab, Asp/Dap, Glu/(d/l)Agl, Glu/Dab, Glu/Dap, Glu/dDap, te Glu/Lys, te R1 je Ac ili Bz, ili gdje X1 i X7 čine par, koji se bira iz skupine koju čine sukcinil/(d/l)Agl, sukcinil/Dab, sukcinil/Dap, sukcinil/Lys, te sukcinil/Orn, a R1 je odsutan; ili
c) navedeni laktam tvori se amidnom vezom između α-amino skupine u X1 i karboksilne skupine u pobočnom lancu u X7, gdje X1 i X7 čine par, koji se bira iz skupine koju čine Ala/Glu, Ala/dGlu, dAla/Glu, dAla/dGlu, Dap(Ac)/Glu, Gly/Asp, Gly/Glu, Gly/dGlu, Leu/Glu, Leu/dGlu, Lys/dGlu, Lys(Ac)/Glu, 2Nal/Glu, Phe/Glu, Phe/dGlu, dPhe/Glu, te dPhe/dGlu, a R1 je odsutan; ili
d) navedeni laktam tvori se amidnom vezom između amino skupine u X1, koja nije ni α- niti amino skupina u pobočnom lancu, i karboksilne skupine u pobočnom lancu u X7, gdje X1 i X7 čine par, koji se bira iz skupine koju čine β-Ala/Asp, β-Ala/Glu, 5-aminovaleril/Asp, 5-aminovaleril/Glu, 4-AMB/Glu, 4-AMPA/Asp, te 4-AMPA/Glu, a R1 je odsutan; ili
e) navedeni laktam tvori se amidnom vezom između α-amino skupine u X2 i karboksilne skupine u pobočnom lancu u X7, gdje X2 i X7 čine par, koji se bira iz skupine koju čine Tyr/Asp, Tyr/Glu, te Tyr/dGlu, a svaki od R1 i X1 je odsutan;
R1 je supstituent na α-amino skupini u X1 kada X1 sadrži α-amino skupinu, a navedena α-amino skupina nije sastavni dio navedene laktamske amidne veze, koji se bira iz skupine koju čine Ac, Bz, te n-heksanoil, ili je odsutan, gdje X1 se bira iz skupine koju čine (d/l)Agl, Asp, Dab, Dap, te Glu;
X1 se bira iz skupine koju čine (d/l)Agl, Ala, β-Ala, dAla, 5-aminovaleril, 4-AMB, 4-AMPA, Asp, Dab, Dap, Dap(Ac), Glu, Gly, Leu, Lys, Lys(Ac), 2Nal, Phe, dPhe, te sukcinil, ili je odsutan;
X3 se bira iz skupine koju čine Arg, Lys, Lys(iPr), te Lys(Me2);
X7 se bira iz skupine koju čine (d/l)Agl, Asp, Dab, Dap, dDap, Glu, dGlu, Lys, te Orn;
X8 se bira iz skupine koju čine β-Ala, Arg, dArg, Gly, Lys, Lys(iPr), te Orn, ili je odsutan;
X9 se bira iz skupine koju čine Gly, 2Nal, d2Nal, te dPhe, ili je odsutan;
X10 je 2Nal, ili je odsutan;
gdje kada X8 je odsutan, svaki od X9 i X10 je odsutan, a kada X9 je odsutan, X10 je odsutan, i
R2 se bira iz skupine koju čine NH2 i NHEt, ili
njegova farmaceutski prihvatljiva sol.
2. Laktamski ciklizirani peptid, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što:
R1 se bira iz skupine koju čine Ac i Bz, ili je odsutan;
X1 se bira iz skupine koju čine β-Ala, 4-AMB, 4-AMPA, Asp, Dab, Dap, Dap(Ac), Glu, 2Nal, Phe, te sukcinil, ili je odsutan;
X3 se bira iz skupine koju čine Arg, Lys, Lys(iPr), te Lys(Me2);
X7 se bira iz skupine koju čine Asp, Dab, Dap, Glu, dGlu, Lys, te Orn;
X8 se bira iz skupine koju čine Arg i Lys, ili je odsutan;
X9 je odsutan;
X10 je odsutan; i
R2 se bira iz skupine koju čine NH2 i NHEt.
3. Laktamski ciklizirani peptid, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što:
R1 se bira iz skupine koju čine Ac i Bz, ili je odsutan;
X1 se bira iz skupine koju čine dAla, 5-aminovaleril, 4-AMPA, Asp, Glu, Leu, Lys(Ac), Phe, dPhe, te sukcinil;
X3 se bira iz skupine koju čine Arg, Lys, Lys(iPr), te Lys(Me2);
X7 se bira iz skupine koju čine (d/l)Agl, Asp, Dab, Dap, dDap, Glu, te Glu;
X8 se bira iz skupine koju čine Arg, dArg, te Lys, ili je odsutan;
X9 je odsutan;
X10 je odsutan; i
R2 se bira iz skupine koju čine NH2 i NHEt.
4. Laktamski ciklizirani peptid, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što:
R1 se bira iz skupine koju čine Ac, Bz, te n-heksanoil, ili je odsutan;
X1 se bira iz skupine koju čine (d/l)Agl, Ala, β-Ala, Asp, Dap, Glu, Gly, Lys, te Phe;
X3 se bira iz skupine koju čine Arg, Lys, Lys(iPr), te Lys(Me2);
X7 se bira iz skupine koju čine (d/l)Agl, Asp, Dap, Glu, te dGlu;
X8 se bira iz skupine koju čine β-Ala, Arg, Gly, Lys, Lys(iPr), te Orn, ili je odsutan;
X9 se bira iz skupine koju čine Gly, 2Nal, d2Nal, te dPhe, ili je odsutan;
X10 je 2Nal, ili je odsutan; i
R2 se bira iz skupine koju čine NH2 i NHEt.
5. Laktamski ciklizirani peptid, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što:
R1 se bira iz skupine koju čine Ac i Bz, ili je odsutan;
X1 se bira iz skupine koju čine Ala, 5-aminovaleril, Asp, Glu, Gly, Phe, dPhe, te sukcinil;
X3 se bira iz skupine koju čine Arg, Lys(iPr), te Lys(Me2);
X7 se bira iz skupine koju čine (d/l)Agl, Asp, Dap, Glu, te Glu;
X8 se bira iz skupine koju čine β-Ala, Arg, Gly, Lys, Lys(iPr), te Orn, ili je odsutan;
X9 se bira iz skupine koju čine Gly, d2Nal, te dPhe, ili je odsutan;
X10 je 2Nal, ili je odsutan; i
R2 se bira iz skupine koju čine NH2 i NHEt.
6. Laktamski ciklizirani peptid, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, 4, ili 5, naznačen time što:
X1 se bira iz skupine koju čine Gly i Phe;
X3 je Lys(iPr); i
X7 je dGlu.
7. Laktamski ciklizirani peptid, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 5, naznačen time što:
R1 je odsutan;
X1 se bira iz skupine koju čine Gly i Phe;
X3 je Lys(iPr);
X7 je dGlu;
X8 se bira iz skupine koju čine Arg i Lys(iPr), ili je odsutan;
X9 je odsutan;
X10 je odsutan; i
R2 se bira iz skupine koju čine NH2 i NHEt.
8. Laktamski ciklizirani peptid, naznačen time što je laktamski ciklizirani peptid formule:
[image]
ili njegova farmaceutski prihvatljiva sol.
9. Laktamski ciklizirani peptid u skladu s patentnim zahtjevom 8, naznačen time što navedena farmaceutski prihvatljiva sol je sol s octenom kiselinom.
10. Farmaceutski pripravak, naznačen time što sadrži laktamski ciklizirani peptid, ili njegovu farmaceutski prihvatljivu sol, u skladu s bilo kojim od patentnih zahtjeva 1-9, i farmaceutski prihvatljivu podlogu, razrjeđivač ili pomoćnu tvar.
11. Laktamski ciklizirani peptid, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačen time što je namijenjen upotrebi u terapiji.
12. Laktamski ciklizirani peptid, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačen time što je namijenjen upotrebi u liječenju reumatoidnog artritisa, plućne fibroze, infekcije HIV-om, ili raka, koji se bira iz skupine koju čine rak dojke, rak gušterače, melanom, rak prostate, rak bubrega, neuroblastom, ne-Hodgkinov limfom, rak pluća, rak jajnika, kolorektalni rak, multipli mijelom, multiformni glioblastom, te kronična limfocitna leukemija.
13. Upotreba laktamski cikliziranog peptida, ili njegove farmaceutski prihvatljive soli, u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačena time što je navedeni laktamski ciklizirani peptid namijenjen proizvodnji medikamenta za liječenje reumatoidnog artritisa, plućne fibroze, infekcije HIV-om, ili raka, koji se bira iz skupine koju čine rak dojke, rak gušterače, melanom, rak prostate, rak bubrega, neuroblastom, ne-Hodgkinov limfom, rak pluća, rak jajnika, kolorektalni rak, multipli mijelom, multiformni glioblastom, te kronična limfocitna leukemija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94080207P | 2007-05-30 | 2007-05-30 | |
| US94099607P | 2007-05-31 | 2007-05-31 | |
| PCT/US2008/064177 WO2008150689A1 (en) | 2007-05-30 | 2008-05-20 | Cyclic peptide cxcr4 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110551T1 true HRP20110551T1 (hr) | 2011-09-30 |
Family
ID=39831600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110551T HRP20110551T1 (hr) | 2007-05-30 | 2011-07-25 | Antagonisti cikličkog peptida cxcr4 |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US7691813B2 (hr) |
| EP (2) | EP2377579A1 (hr) |
| JP (1) | JP5358564B2 (hr) |
| KR (2) | KR101319740B1 (hr) |
| CN (1) | CN101678213B (hr) |
| AR (1) | AR066648A1 (hr) |
| AT (1) | ATE516853T1 (hr) |
| AU (1) | AU2008260326B2 (hr) |
| BR (1) | BRPI0812134A2 (hr) |
| CA (1) | CA2688574C (hr) |
| CL (1) | CL2008001467A1 (hr) |
| CO (1) | CO6241137A2 (hr) |
| CR (1) | CR11105A (hr) |
| CY (1) | CY1111815T1 (hr) |
| DK (1) | DK2160221T3 (hr) |
| DO (1) | DOP2009000270A (hr) |
| EA (1) | EA017716B1 (hr) |
| GT (1) | GT200900304A (hr) |
| HK (1) | HK1141474A1 (hr) |
| HR (1) | HRP20110551T1 (hr) |
| IL (1) | IL201685A (hr) |
| JO (1) | JO2776B1 (hr) |
| MA (1) | MA31666B1 (hr) |
| MX (1) | MX2009012952A (hr) |
| MY (1) | MY149432A (hr) |
| NZ (1) | NZ580849A (hr) |
| PE (1) | PE20090299A1 (hr) |
| PL (1) | PL2160221T3 (hr) |
| PT (1) | PT2160221E (hr) |
| TN (1) | TN2009000496A1 (hr) |
| TW (1) | TWI423987B (hr) |
| WO (1) | WO2008150689A1 (hr) |
| ZA (1) | ZA200908345B (hr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2942798B1 (fr) | 2009-03-05 | 2011-04-08 | Centre Nat Rech Scient | Peptides utilisables pour le traitement de la leucemie lymphoide chronique |
| IT1397901B1 (it) * | 2010-01-26 | 2013-02-04 | Consiglio Nazionale Ricerche | Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico. |
| WO2012118124A1 (ja) * | 2011-03-01 | 2012-09-07 | 国立大学法人京都大学 | 新規ケモカイン受容体拮抗剤 |
| US9079939B2 (en) * | 2011-06-07 | 2015-07-14 | Polyphor Ag | Beta-hairpin peptidomimetics as CXC4 antagonists |
| WO2013044500A1 (zh) * | 2011-09-30 | 2013-04-04 | Cheng Yun | 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用 |
| WO2013060865A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| EP2979991A1 (en) | 2014-07-31 | 2016-02-03 | Greif International Holding BV. | Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat. |
| ES2764840T3 (es) | 2015-01-28 | 2020-06-04 | Univ Bordeaux | Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica |
| WO2017176565A1 (en) | 2016-04-07 | 2017-10-12 | Eli Lilly And Company | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor |
| EP3509612A4 (en) * | 2016-09-06 | 2021-07-21 | Mainline Biosciences | CXCR4 ANTAGONISTS AND METHOD OF USE |
| CN106841624B (zh) * | 2017-01-26 | 2019-02-22 | 庄磊靓 | 抗人cd4和抗人cd184单克隆抗体作为标志物的应用 |
| US11123437B2 (en) | 2017-09-05 | 2021-09-21 | Mainline Biosciences, Inc. | Selective CXCR4 binding peptide conjugate and methods for making and using the same |
| JP2020532496A (ja) * | 2017-09-05 | 2020-11-12 | メインライン バイオサイエンシズ | 高親和性ｃｘｃｒ４選択的結合抱合体およびその使用方法 |
| US11771736B2 (en) * | 2017-12-21 | 2023-10-03 | Mainline Biosciences (Shanghai) Co., Ltd. | Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same |
| JP2021165234A (ja) * | 2018-07-03 | 2021-10-14 | 富士フイルム富山化学株式会社 | Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体 |
| US11639373B2 (en) | 2018-09-12 | 2023-05-02 | Technische Universität München | Therapeutic and diagnostic agents for cancer |
| EP3849997B1 (en) | 2018-09-12 | 2024-05-01 | Technische Universität München | Cxcr4-targeted diagnostic and therapeutic agents with reduced species selectivity |
| JP2022529007A (ja) * | 2019-04-18 | 2022-06-16 | プロビンシャル・ヘルス・サービシーズ・オーソリティ | 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物 |
| EP4097120A4 (en) * | 2020-01-26 | 2024-05-01 | Mainline Biosciences Shanghai Co Ltd | ISOTOPE-LABELED CXCR4 SELECTIVELY BINDING PEPTIDE CONJUGATE AND METHODS OF MAKING AND USE THEREOF |
| US20240124517A1 (en) * | 2020-12-25 | 2024-04-18 | Chugai Seiyaku Kabushiki Kaisha | Method for producing peptide compound containing n-substituted-amino acid residue |
| EP4043041A1 (en) | 2021-02-15 | 2022-08-17 | Technische Universität München | Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof |
| WO2023201435A1 (en) * | 2022-04-20 | 2023-10-26 | Provincial Health Services Authority | Cxcr4-targeting compounds, and methods of making and using the same |
| CN115060901A (zh) * | 2022-06-21 | 2022-09-16 | 中国医学科学院基础医学研究所 | 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4391123B2 (ja) * | 2002-10-24 | 2009-12-24 | 株式会社オーファンリンク | 新規ｃｘｃｒ４アンタゴニスト |
| CA2643744A1 (en) * | 2006-02-27 | 2007-08-30 | Technische Universitaet Muenchen | Cancer imaging and treatment |
-
2008
- 2008-05-20 CL CL2008001467A patent/CL2008001467A1/es unknown
- 2008-05-20 AU AU2008260326A patent/AU2008260326B2/en not_active Ceased
- 2008-05-20 EA EA200971129A patent/EA017716B1/ru not_active IP Right Cessation
- 2008-05-20 WO PCT/US2008/064177 patent/WO2008150689A1/en active Application Filing
- 2008-05-20 KR KR1020117026680A patent/KR101319740B1/ko not_active IP Right Cessation
- 2008-05-20 NZ NZ580849A patent/NZ580849A/en not_active IP Right Cessation
- 2008-05-20 JO JO2008229A patent/JO2776B1/en active
- 2008-05-20 PT PT08769524T patent/PT2160221E/pt unknown
- 2008-05-20 EP EP11172401A patent/EP2377579A1/en not_active Withdrawn
- 2008-05-20 TW TW097118554A patent/TWI423987B/zh not_active IP Right Cessation
- 2008-05-20 AR ARP080102137A patent/AR066648A1/es unknown
- 2008-05-20 MX MX2009012952A patent/MX2009012952A/es active IP Right Grant
- 2008-05-20 KR KR1020097024829A patent/KR101169846B1/ko not_active IP Right Cessation
- 2008-05-20 CA CA2688574A patent/CA2688574C/en not_active Expired - Fee Related
- 2008-05-20 US US12/123,574 patent/US7691813B2/en not_active Ceased
- 2008-05-20 AT AT08769524T patent/ATE516853T1/de active
- 2008-05-20 MY MYPI20095053A patent/MY149432A/en unknown
- 2008-05-20 BR BRPI0812134-6A2A patent/BRPI0812134A2/pt not_active IP Right Cessation
- 2008-05-20 EP EP08769524A patent/EP2160221B1/en active Active
- 2008-05-20 PL PL08769524T patent/PL2160221T3/pl unknown
- 2008-05-20 JP JP2010510418A patent/JP5358564B2/ja not_active Expired - Fee Related
- 2008-05-20 DK DK08769524.3T patent/DK2160221T3/da active
- 2008-05-20 PE PE2008000868A patent/PE20090299A1/es not_active Application Discontinuation
- 2008-05-20 CN CN2008800178577A patent/CN101678213B/zh not_active Expired - Fee Related
-
2009
- 2009-10-22 IL IL201685A patent/IL201685A/en not_active IP Right Cessation
- 2009-11-10 CR CR11105A patent/CR11105A/es not_active Application Discontinuation
- 2009-11-25 ZA ZA2009/08345A patent/ZA200908345B/en unknown
- 2009-11-26 GT GT200900304A patent/GT200900304A/es unknown
- 2009-11-26 TN TNP2009000496A patent/TN2009000496A1/fr unknown
- 2009-11-27 CO CO09135750A patent/CO6241137A2/es active IP Right Grant
- 2009-11-27 DO DO2009000270A patent/DOP2009000270A/es unknown
- 2009-12-21 MA MA32439A patent/MA31666B1/fr unknown
-
2010
- 2010-01-25 US US12/692,788 patent/US20100130409A1/en not_active Abandoned
- 2010-08-20 HK HK10107961.8A patent/HK1141474A1/xx not_active IP Right Cessation
- 2010-09-10 US US12/807,694 patent/USRE42274E1/en not_active Expired - Fee Related
-
2011
- 2011-07-25 HR HR20110551T patent/HRP20110551T1/hr unknown
- 2011-09-07 CY CY20111100861T patent/CY1111815T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110551T1 (hr) | Antagonisti cikličkog peptida cxcr4 | |
| JP2010529957A5 (hr) | ||
| CN1953989B (zh) | 作为细胞抑制剂的在7位与环肽缀合的喜树碱 | |
| RS53782B1 (en) | TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS | |
| JP2013509861A5 (hr) | ||
| RS54215B1 (en) | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
| DE602007011901D1 (de) | Ptiden und zellpenetrierenden peptiden gekoppelt a | |
| UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
| EP2590992A4 (en) | OPIOID RECEPTOR AGONIST ANALOGUES OF ENDOMORPHINS | |
| PT1987063E (pt) | Péptidos e derivados peptídicos, a produção destes bem como a sua utilização para a preparação de uma composição farmacêutica terapeuticamente e/ou preventivamente activa | |
| Matheson et al. | Establishing the structure-activity relationship of teixobactin | |
| Einsiedel et al. | Peptide backbone modifications on the C-terminal hexapeptide of neurotensin | |
| Gattu et al. | Conjugation as a tool in therapeutics: Role of amino acids/peptides-bioactive (including Heterocycles) hybrid molecules in treating infectious diseases | |
| JPWO2020230780A5 (hr) | ||
| WO2008070049A8 (en) | Peptide and treatment for hiv-1 infection | |
| RS51950B (en) | CYCLIC PEPTIDE ANTAGONISTS CXCR4 | |
| CN101010103A (zh) | 在20位与整联蛋白拮抗剂缀合的喜树碱衍生物 | |
| MXPA06012885A (es) | 7-t-butoximinometilcamptotecina conjugada en posicion 20 con antagonistas de integrina. | |
| Aufort et al. | Synthesis and biochemical evaluation of a cyclic RGD oxorhenium complex as new ligand of αVβ3 integrin | |
| ES2367941T3 (es) | Antagonistas cíclicos peptídicos de cxcr4. | |
| Parente | Diketopiperazines as scaffold for the synthesis of new compounds modulating protein-protein interactions and functions | |
| EP3927737A1 (en) | Par4 derived peptides, analogs and uses thereof | |
| TH106960B (th) | ไซคลิกเพพไทด์ cxcr4 แอนทาโกนิสต์ | |
| Matsoukas et al. | Drug discovery and design: medical aspects | |
| JP2012180315A (ja) | タンパク質チロシンキナーゼ阻害活性を有する環状ペプチド化合物 |